

according to Regulation UK SI 2019/758 and UK SI 2020/1577 as amended

Creation Date 18-Feb-2020 Revision Date 29-Mar-2024 Revision Number 2

# SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

#### 1.1. Product identifier

Product Description: Pitavastatin calcium

Cat No.: H36623

**Synonyms** (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic

acid,monocalcium salt; Itabastatin; Itavastatin; NK 104;

**CAS No** 147526-32-7 **EC No** 807-641-2

Molecular Formula C50 H46 Ca F2 N2 O8

#### 1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Laboratory chemicals.
Uses advised against No Information available

### 1.3. Details of the supplier of the safety data sheet

Company

Avocado Research Chemicals Ltd. (Part of Thermo Fisher Scientific)

Shore Road, Heysham Lancashire, LA3 2XY, United Kingdom

Office Tel: +44 (0) 1524 850506 Office Fax: +44 (0) 1524 850608

E-mail address begel.sdsdesk@thermofisher.com

1.4. Emergency telephone number

For information **US** call: 001-800-227-6701 / **Europe** call: +32 14 57 52 11 Emergency Number **US**:001-201-796-7100 / **Europe**: +32 14 57 52 99 **CHEMTREC** Tel. No. **US**:001-800-424-9300 / **Europe**:001-703-527-3887

### **SECTION 2: HAZARDS IDENTIFICATION**

### 2.1. Classification of the substance or mixture

#### GHS Classification - According to GB-CLP Regulations UK SI 2019/720 and UK SI 2020/1567

### **Physical hazards**

Based on available data, the classification criteria are not met

#### **Health hazards**

### Pitavastatin calcium Revision Date 29-Mar-2024

Skin Corrosion/IrritationCategory 2 (H315)Serious Eye Damage/Eye IrritationCategory 2 (H319)CarcinogenicityCategory 2 (H351)Specific target organ toxicity - (single exposure)Category 3 (H335)

**Environmental hazards** 

Based on available data, the classification criteria are not met

Full text of Hazard Statements: see section 16

#### 2.2. Label elements



### Signal Word

### Warning

### **Hazard Statements**

H315 - Causes skin irritation

H319 - Causes serious eye irritation

H335 - May cause respiratory irritation

H351 - Suspected of causing cancer

### **Precautionary Statements**

P302 + P352 - IF ON SKIN: Wash with plenty of soap and water

P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing

P304 + P340 - IF INHALED: Remove person to fresh air and keep comfortable for breathing

P312 - Call a POISON CENTER or doctor if you feel unwell

P280 - Wear protective gloves/protective clothing/eye protection/face protection

### 2.3. Other hazards

This product does not contain any known or suspected endocrine disruptors

### **SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS**

### 3.1. Substances

Component	CAS No	EC No	Weight %	GHS Classification - According to
				GB-CLP Regulations UK SI 2019/720 and
				UK SI 2020/1567
Pitavastatin (calcium salt)	147526-32-7	807-641-2	<=100	Skin Irrit. 2 (H315)
				Eye Irrit. 2 (H319)
				STOT SE 3 (H335)
				Carc. 2 (H351)

Pitavastatin calcium Revision Date 29-Mar-2024

Full text of Hazard Statements: see section 16

### **SECTION 4: FIRST AID MEASURES**

### 4.1. Description of first aid measures

**General Advice** If symptoms persist, call a physician.

**Eye Contact** Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. Get

medical attention.

**Skin Contact** Wash off immediately with plenty of water for at least 15 minutes. If skin irritation persists,

call a physician.

**Ingestion** Clean mouth with water and drink afterwards plenty of water. Get medical attention if

symptoms occur.

**Inhalation** Remove to fresh air. If not breathing, give artificial respiration. Get medical attention if

symptoms occur.

**Self-Protection of the First Aider** No special precautions required.

### 4.2. Most important symptoms and effects, both acute and delayed

None reasonably foreseeable.

#### 4.3. Indication of any immediate medical attention and special treatment needed

Notes to Physician Treat symptomatically.

### **SECTION 5: FIREFIGHTING MEASURES**

### 5.1. Extinguishing media

#### **Suitable Extinguishing Media**

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Dry chemical, CO<sub>2</sub>, water spray or alcohol-resistant foam.

### Extinguishing media which must not be used for safety reasons

No information available.

### 5.2. Special hazards arising from the substance or mixture

Thermal decomposition can lead to release of irritating gases and vapors.

### **Hazardous Combustion Products**

Carbon monoxide (CO), Carbon dioxide (CO2), Nitrogen oxides (NOx), Hydrogen fluoride.

#### 5.3. Advice for firefighters

As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective gear.

### **SECTION 6: ACCIDENTAL RELEASE MEASURES**

### 6.1. Personal precautions, protective equipment and emergency procedures

Ensure adequate ventilation. Use personal protective equipment as required. Avoid dust formation.

Pitavastatin calcium Revision Date 29-Mar-2024

#### 6.2. Environmental precautions

Should not be released into the environment.

### 6.3. Methods and material for containment and cleaning up

Sweep up and shovel into suitable containers for disposal. Keep in suitable, closed containers for disposal.

#### 6.4. Reference to other sections

Refer to protective measures listed in Sections 8 and 13.

### **SECTION 7: HANDLING AND STORAGE**

#### 7.1. Precautions for safe handling

Wear personal protective equipment/face protection. Ensure adequate ventilation. Avoid ingestion and inhalation. Avoid dust formation. Do not get in eyes, on skin, or on clothing.

#### **Hygiene Measures**

Handle in accordance with good industrial hygiene and safety practice. Keep away from food, drink and animal feeding stuffs. Do not eat, drink or smoke when using this product. Remove and wash contaminated clothing and gloves, including the inside, before re-use. Wash hands before breaks and after work.

### 7.2. Conditions for safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated place. To maintain product quality: Store in freezer.

Technical Rules for Hazardous Substances (TRGS) 510 Class 11 Storage Class (LGK) (Germany)

#### 7.3. Specific end use(s)

Use in laboratories

### **SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION**

### 8.1. Control parameters

#### **Exposure limits**

This product, as supplied, does not contain any hazardous materials with occupational exposure limits established by the region specific regulatory bodies

### **Biological limit values**

This product, as supplied, does not contain any hazardous materials with biological limits established by the region specific regulatory bodies

#### Derived No Effect Level (DNEL) / Derived Minimum Effect Level (DMEL)

No information available

Pitavastatin calcium Revision Date 29-Mar-2024

### **Predicted No Effect Concentration (PNEC)**

No information available.

### 8.2. Exposure controls

### **Engineering Measures**

None under normal use conditions. Ensure that eyewash stations and safety showers are close to the workstation location.

Personal protective equipment

**Eye Protection** Goggles (European standard - EN 166)

Hand Protection Protective gloves

PVC		Glove material Nitrile rubber Neoprene Natural rubber	Breakthrough time See manufacturers recommendations	Glove thickness	EU standard EN 374	Glove comments (minimum requirement)
-----	--	---	---	-----------------	-----------------------	---

**Skin and body protection** Long sleeved clothing.

Inspect gloves before use.

Please observe the instructions regarding permeability and breakthrough time which are provided by the supplier of the gloves. (Refer to manufacturer/supplier for information)

Ensure gloves are suitable for the task: Chemical compatability, Dexterity, Operational conditions, User susceptibility, e.g. sensitisation effects, also take into consideration the specific local conditions under which the product is used, such as the danger of cuts, abrasion.

Remove gloves with care avoiding skin contamination.

**Respiratory Protection** No protective equipment is needed under normal use conditions.

Large scale/emergency use Use a NIOSH/MSHA or European Standard EN 136 approved respirator if exposure limits

are exceeded or if irritation or other symptoms are experienced

Recommended Filter type: Particle filter

Small scale/Laboratory use Maintain adequate ventilation

**Environmental exposure controls** No information available.

### **SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES**

### 9.1. Information on basic physical and chemical properties

Physical State Solid

Appearance White to off-white
Odor No information available
Odor Threshold No data available
Melting Point/Range No data available
Softening Point No data available
Boiling Point/Range No information available

Flammability (liquid) Not applicable Solid

Flammability (solid,gas) No information available

Pitavastatin calcium Revision Date 29-Mar-2024

Solid

Solid

Explosion Limits No data available

Flash Point No information available Method - No information available

Autoignition Temperature
Decomposition Temperature
pH

No data available
No data available
No information available

Viscosity Not applicable

Water Solubility
Solubility
No information available
No information available

Partition Coefficient (n-octanol/water)

Vapor Pressure
Density / Specific Gravity
Bulk Density
Vapor Density
No data available
No data available
No data available
Not applicable

Particle characteristics No data available

9.2. Other information

Molecular Formula C50 H46 Ca F2 N2 O8

Molecular Weight 880.99

Evaporation Rate Not applicable - Solid

### **SECTION 10: STABILITY AND REACTIVITY**

10.1. Reactivity

None known, based on information available

10.2. Chemical stability

Stable under recommended storage conditions.

10.3. Possibility of hazardous reactions

Hazardous PolymerizationNo information available.Hazardous ReactionsNone under normal processing.

10.4. Conditions to avoid

Extremes of temperature and direct sunlight. Incompatible products.

10.5. Incompatible materials

Strong oxidizing agents.

10.6. Hazardous decomposition products

Carbon monoxide (CO). Carbon dioxide (CO<sub>2</sub>). Nitrogen oxides (NOx). Hydrogen fluoride.

### **SECTION 11: TOXICOLOGICAL INFORMATION**

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

**Product Information**No acute toxicity information is available for this product The toxicological properties have

not been fully investigated

(a) acute toxicity;

Oral No data available
Dermal No data available
Inhalation No data available

\_\_\_\_\_

Pitavastatin calcium Revision Date 29-Mar-2024

(b) skin corrosion/irritation; Category 2

(c) serious eye damage/irritation; Category 2

(d) respiratory or skin sensitization;

RespiratoryNo data availableSkinNo data available

(e) germ cell mutagenicity; No data available

(f) carcinogenicity; Category 2

There are no known carcinogenic chemicals in this product

(g) reproductive toxicity; No data available

(h) STOT-single exposure; Category 3

Results / Target organs Respiratory system.

(i) STOT-repeated exposure; No data available

Target Organs None known.

(j) aspiration hazard; Not applicable

Solid

Other Adverse Effects No information available

Symptoms / effects,both acute and No information available.

delayed

11.2. Information on other hazards

Endocrine Disrupting Properties Assess endocrine disrupting properties for human health. This product does not contain any

known or suspected endocrine disruptors.

### **SECTION 12: ECOLOGICAL INFORMATION**

12.1. Toxicity

**Ecotoxicity effects**Contains no substances known to be hazardous to the environment or that are not

degradable in waste water treatment plants.

12.2. Persistence and degradability

**Persistence** Persistence is unlikely, based on information available.

12.3. Bioaccumulative potential Bioaccumulation is unlikely

Pitavastatin calcium Revision Date 29-Mar-2024

12.5. Results of PBT and vPvB

assessment

12.4. Mobility in soil

No data available for assessment.

May be mobile in the environment.

12.6. Endocrine disrupting

properties

**Endocrine Disruptor Information** 

This product does not contain any known or suspected endocrine disruptors

12.7. Other adverse effects

Persistent Organic Pollutant Ozone Depletion Potential This product does not contain any known or suspected substance This product does not contain any known or suspected substance

### **SECTION 13: DISPOSAL CONSIDERATIONS**

13.1. Waste treatment methods

Waste from Residues/Unused

**Products** 

Waste is classified as hazardous. Dispose of in accordance with the European Directives

on waste and hazardous waste. Dispose of in accordance with local regulations.

**Contaminated Packaging** Dispose of this container to hazardous or special waste collection point.

European Waste Catalogue (EWC) According to the European Waste Catalog, Waste Codes are not product specific, but

application specific.

Other Information Waste codes should be assigned by the user based on the application for which the product

was used. Do not empty into drains.

### **SECTION 14: TRANSPORT INFORMATION**

IMDG/IMO Not regulated

14.1. UN number

14.2. UN proper shipping name

14.3. Transport hazard class(es)

14.4. Packing group

ADR Not regulated

14.1. UN number

14.2. UN proper shipping name

14.3. Transport hazard class(es)

14.4. Packing group

IATA Not regulated

14.1. UN number

14.2. UN proper shipping name

14.3. Transport hazard class(es)

14.4. Packing group

Pitavastatin calcium Revision Date 29-Mar-2024

**14.5. Environmental hazards**No hazards identified

**14.6. Special precautions for user** No special precautions required.

14.7. Maritime transport in bulk according to IMO instruments

Not applicable, packaged goods

### **SECTION 15: REGULATORY INFORMATION**

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

#### **International Inventories**

Europe (EINECS/ELINCS/NLP), China (IECSC), Taiwan (TCSI), Korea (KECL), Japan (ENCS), Japan (ISHL), Canada (DSL/NDSL), Australia (AICS), New Zealand (NZIoC), Philippines (PICCS). US EPA (TSCA) - Toxic Substances Control Act, (40 CFR Part 710)

Component	CAS No	EINECS	ELINCS	NLP	IECSC	TCSI	KECL	ENCS	ISHL
Pitavastatin (calcium salt)	147526-32-7	-	-	ı	-	X	-	-	X
_									

Component	CAS No	TSCA	TSCA Inventory notification - Active-Inactive	DSL	NDSL	AICS	NZIoC	PICCS
Pitavastatin (calcium salt)	147526-32-7	-	-	-	-	-	-	-

**Legend:** X - Listed '-' - Not Listed **KECL** - NIER number or KE number (http://ncis.nier.go.kr/en/main.do)

### Authorisation/Restrictions according to EU REACH

Not applicable

	Component	CAS No	REACH (1907/2006) - Annex XIV - Substances Subject to Authorization		REACH Regulation (EC 1907/2006) article 59 - Candidate List of Substances of Very High Concern (SVHC)
Ī	Pitavastatin (calcium salt)	147526-32-7	-	-	-

#### Seveso III Directive (2012/18/EC)

Component	CAS No	Seveso III Directive (2012/18/EC) - Seveso III Directive (2012/18/		
		Qualifying Quantities for Major Accident	Qualifying Quantities for Safety Report	
		Notification	Requirements	
Pitavastatin (calcium salt)	147526-32-7	Not applicable	Not applicable	

# Regulation (EC) No 649/2012 of the European Parliament and of the Council of 4 July 2012 concerning the export and import of dangerous chemicals

Not applicable

### Contains component(s) that meet a 'definition' of per & poly fluoroalkyl substance (PFAS)?

See table for values

Component	OECD PFAS	US (EPA) PFAS	EU (ECHA) PFAS	UK (HSE) PFAS	Chemsec PFAS (Sin List)
Pitavastatin (calcium salt) (CAS #: 147526-32-7)	-	-	Listed	-	-

### **PFAS Legend**

Listed = Meets the PFAS definition of the named authority

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work .

Pitavastatin calcium Revision Date 29-Mar-2024

#### **National Regulations**

UK - Take note of Control of Substances Hazardous to Health Regulations (COSHH) 2002 and 2005 Amendment

**WGK Classification** Water endangering class = 3 (self classification)

#### 15.2. Chemical safety assessment

A Chemical Safety Assessment/Report (CSA/CSR) has not been conducted

### **SECTION 16: OTHER INFORMATION**

### Full text of H-Statements referred to under sections 2 and 3

H315 - Causes skin irritation

H319 - Causes serious eye irritation

H335 - May cause respiratory irritation

H351 - Suspected of causing cancer

#### Legend

**CAS** - Chemical Abstracts Service

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

Substances/EU List of Notified Chemical Substances

PICCS - Philippines Inventory of Chemicals and Chemical Substances

IECSC - Chinese Inventory of Existing Chemical Substances

**KECL** - Korean Existing and Evaluated Chemical Substances

EINECS/ELINCS - European Inventory of Existing Commercial Chemical DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

**ENCS** - Japanese Existing and New Chemical Substances

AICS - Australian Inventory of Chemical Substances

WEL - Workplace Exposure Limit

**ACGIH** - American Conference of Governmental Industrial Hygienists

**DNEL** - Derived No Effect Level

RPE - Respiratory Protective Equipment

LC50 - Lethal Concentration 50%

NOEC - No Observed Effect Concentration

PBT - Persistent, Bioaccumulative, Toxic

TWA - Time Weighted Average

IARC - International Agency for Research on Cancer

Predicted No Effect Concentration (PNEC)

NZIoC - New Zealand Inventory of Chemicals

LD50 - Lethal Dose 50%

EC50 - Effective Concentration 50%

POW - Partition coefficient Octanol:Water

vPvB - very Persistent, very Bioaccumulative

ADR - European Agreement Concerning the International Carriage of

Dangerous Goods by Road

IMO/IMDG - International Maritime Organization/International Maritime

Dangerous Goods Code

OECD - Organisation for Economic Co-operation and Development

**BCF** - Bioconcentration factor

ICAO/IATA - International Civil Aviation Organization/International Air **Transport Association** 

MARPOL - International Convention for the Prevention of Pollution from

Ships

ATE - Acute Toxicity Estimate

VOC - (Volatile Organic Compound)

### Key literature references and sources for data

https://echa.europa.eu/information-on-chemicals

Suppliers safety data sheet, Chemadvisor - LOLI, Merck index, RTECS

#### **Training Advice**

Chemical hazard awareness training, incorporating labelling, Safety Data Sheets (SDS), Personal Protective Equipment (PPE) and hygiene.

**Prepared By** Health, Safety and Environmental Department

**Creation Date** 18-Feb-2020 **Revision Date** 29-Mar-2024

Pitavastatin calcium Revision Date 29-Mar-2024

**Revision Summary** 

New emergency telephone response service provider.

This safety data sheet complies with Regulation UK SI 2019/758 and UK SI 2020/1577 as amended.

### **Disclaimer**

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text

**End of Safety Data Sheet**